Jump to content

Main menu Navigation ●Main page ●Contents ●Current events ●Random article ●About Wikipedia ●Contact us ●Donate Contribute ●Help ●Learn to edit ●Community portal ●Recent changes ●Upload file

●Create account ●Log in ●Create account ● Log in Pages for logged out editors learn more ●Contributions ●Talk

(Top) 1 See also 2 References

IM-250

Add links ●Article ●Talk ●Read ●Edit ●View history Tools Actions ●Read ●Edit ●View history General ●What links here ●Related changes ●Upload file ●Special pages ●Permanent link ●Page information ●Cite this page ●Get shortened URL ●Download QR code ●Wikidata item Print/export ●Download as PDF ●Printable version Appearance From Wikipedia, the free encyclopedia

IM-250
Names

IUPAC name (S)-2-[4-(2,5-difluorophenyl)phenyl]-N-methyl-N-[4-methyl-5-(methylsulfonimidoyl)-1,3-thiazol-2-yl]acetamide
Identifiers
CAS Number	2305750-23-4^N
3D model (JSmol)	Interactive image
PubChem CID	138523647
InChI InChI=1S/C20H19F2N3O2S2/c1-12-19(29(3,23)27)28-20(24-12)25(2)18(26)10-13-4-6-14(7-5-13)16-11-15(21)8-9-17(16)22/h4-9,11,23H,10H2,1-3H3 Key: JDZTWDISDHLKCR-UHFFFAOYSA-N
SMILES CC1=C(SC(=N1)N(C)C(=O)CC2=CC=C(C=C2)C3=C(C=CC(=C3)F)F)S(=N)(=O)C
Properties
Chemical formula	C₂₀H₁₉F₂N₃O₂S₂
Molar mass	435.51 g·mol⁻¹
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

IM-250 is an anti-herpetic drug candidate^[1] developed by Innovative Molecules Gmbh.^[2] The drug was conceived by a chemist at the company, who hypothesized that swapping the sulfonamide function group on pritelivir for a sulfoximine would reduce off-target effects. Chemists at the company also tweaked an aromatic group on pritelivir to make their drug candidate more likely to enter the central nervous system, where it could go after latent HSV.^[3]

Innovative Molecules is trying to raise 20 million euro for a clinical trial on humans.^[4]

References

[edit]

^ Gege, Christian; Bravo, Fernando J.; Uhlig, Nadja; Hagmaier, Timo; Schmachtenberg, Rosanne; Elis, Julia; Burger-Kentischer, Anke; Finkelmeier, Doris; Hamprecht, Klaus; Grunwald, Thomas; Bernstein, David I.; Kleymann, Gerald (16 June 2021). "A helicase-primase drug candidate with sufficient target tissue exposure affects latent neural herpes simplex virus infections". Science Translational Medicine. 13 (598). doi:10.1126/scitranslmed.abf8668. PMID 34135112.

^ "Drug Candidate Shows 'Potent Anti-Herpes Activity'". 17 June 2021.

^ "Small molecule fights active and latent herpes infections in rodents".

^ Lücking, Ulrich (7 October 2022). "New Opportunities for the Utilization of the Sulfoximine Group in Medicinal Chemistry from the Drug Designer's Perspective". Chemistry – A European Journal. 28 (56): e202201993. doi:10.1002/chem.202201993. PMID 35789054.

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=IM-250&oldid=1227453415" Categories: ●Sulfoximines ●Thiazoles ●Carboxamides ●Anti-herpes virus drugs ●Antiinfective agent stubs Hidden categories: ●Articles with short description ●Short description is different from Wikidata ●Articles without InChI source ●Chemical pages without ChemSpiderID ●Articles without EBI source ●Articles without KEGG source ●Articles without UNII source ●Articles with changed CASNo identifier ●Articles containing unverified chemical infoboxes ●Chembox image size set ●Short description matches Wikidata ●All stub articles ●This page was last edited on 5 June 2024, at 20:23 (UTC). ●Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization. ●Privacy policy ●About Wikipedia ●Disclaimers ●Contact Wikipedia ●Code of Conduct ●Developers ●Statistics ●Cookie statement ●Mobile view